Justin B. Klee - 05 May 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Justin B. Klee
Issuer symbol
AMLX
Transactions as of
05 May 2022
Net transactions value
+$123,772
Form type
4
Filing time
06 May 2022, 16:05:42 UTC
Previous filing
06 Jan 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $123,772 +334,520 +13% $0.3700* 2,898,585 05 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Options Exercise $0 -334,520 -100% $0.000000* 0 05 May 2022 Common Stock 334,520 $0.3700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable.